Search Results - "Pethe, Abhijit"

Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids by Bateman, Eric D, Guerreros, Alfredo G, Brockhaus Florian, Holzhauer Bjorn, Pethe Abhijit, Kay, Richard A, Townley, Robert G

“…Dose-related efficacy and safety of fevipiprant (QAW039), an oral DP2 (CRTh2) receptor antagonist, was assessed in patients with allergic asthma uncontrolled…”
Get full text

Ge (100) and (111) N- and P-FETs With High Mobility and Low- T Mobility Characterization by Kuzum, D., Pethe, A.J., Krishnamohan, T., Saraswat, K.C.

“…In this paper, we demonstrate high-mobility bulk Ge N- and P-FETs with GeON gate dielectric. The highest electron mobility to date in Ge is reported, and two…”
Get full text

Ge-Interface Engineering With Ozone Oxidation for Low Interface-State Density by Kuzum, D., Krishnamohan, T., Pethe, A.J., Okyay, A.K., Oshima, Y., Yun Sun, McVittie, J.P., Pianetta, P.A., McIntyre, P.C., Saraswat, K.C.

“…Passivation of Ge has been a critical issue for Ge MOS applications in future technology nodes. In this letter, we introduce ozone oxidation to engineer…”
Get full text

Ligelizumab treatment for severe asthma: learnings from the clinical development programme by Trischler, Jordis, Bottoli, Ivan, Janocha, Reinhold, Heusser, Christoph, Jaumont, Xavier, Lowe, Phil, Gautier, Aurelie, Pethe, Abhijit, Woessner, Ralph, Zerwes, Hans‐Günter, Zielen, Stefan

“…Objective Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than…”
Get full text

One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies by Chapman, Kenneth, van Zyl-Smit, Richard, Maspero, Jorge, Kerstjens, Huib A M, Gon, Yasuhiro, Hosoe, Motoi, Tanase, Ana-Maria, Pethe, Abhijit, Shu, Xu, D’Andrea, Peter

“…BackgroundDespite currently available standard-of-care inhaled corticosteroid (ICS)/long-acting β2-agonist therapies, a substantial proportion of patients with…”
Get full text

Confidence intervals for exposure‐adjusted rate differences in randomized trials by Scosyrev, Emil, Pethe, Abhijit

“…Exposure‐adjusted event rate is a quantity often used in clinical trials to describe average event count per unit of person‐time. The event count may represent…”
Get full text

Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study by Kerstjens, Huib A M, Maspero, Jorge, Chapman, Kenneth R, van Zyl-Smit, Richard N, Hosoe, Motoi, Tanase, Ana-Maria, Lavecchia, Catherine, Pethe, Abhijit, Shu, Xu, D'Andrea, Peter

“…Patients with asthma who are inadequately controlled on inhaled corticosteroid–long-acting β2-adrenoceptor agonist (ICS–LABA) combinations might benefit from…”
Get full text

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study by van Zyl-Smit, Richard N, Krüll, Matthias, Gessner, Christian, Gon, Yasuhiro, Noga, Oliver, Richard, Alexia, de los Reyes, Amy, Shu, Xu, Pethe, Abhijit, Tanase, Ana-Maria, D'Andrea, Peter

“…Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and long-acting β2-adrenoceptor agonists (LABA) are considered safe and efficacious in asthma…”
Get full text

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials by Scosyrev, Emil, van Zyl-Smit, Richard, Kerstjens, Huib, Gessner, Christian, Kornmann, Oliver, Jain, Devendra, Aubrun, Elodie, D'Andrea, Peter, Hosoe, Motoi, Pethe, Abhijit, Brittain, Dominic

“…To evaluate cardiovascular safety of two new inhaled fixed-dose combinations for treatment of asthma: (i) the inhaled corticosteroid/long-acting beta2-agonist…”
Get full text

Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies by Sagara, Hironori, D'Andrea, Peter, Tanase, Ana-Maria, Pethe, Abhijit, Tanaka, Yukina, Matsuo, Kazutaka, Hosoe, Motoi, Nakamura, Yoichi

“…The 52-week long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) high-dose (150/50/160 µg) and IND/MF…”
Get full text

High performance germanium MOSFETs by Saraswat, Krishna, Chui, Chi On, Krishnamohan, Tejas, Kim, Donghyun, Nayfeh, Ammar, Pethe, Abhijit

“…Ge is a very promising material as future channel materials for nanoscale MOSFETs due to its high mobility and thus a higher source injection velocity, which…”
Get full text

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma by Brittain, Dominic, D’Andrea, Peter, Gruen, Emilie, Hosoe, Motoi, Jain, Devendra, Jauernig, Juergen, Pethe, Abhijit, Scosyrev, Emil, Tanase, Ana-Maria, Tillmann, Hanns-Christian

“…A novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by…”
Get full text

True Random Number Generator Implemented in ReRAM Crossbar Based on Static Stochasticity of ReRAMs by Patni, Tanay, Pethe, Abhijit

“…True Random Number Generators (TRNG) find applications in various fields, especially hardware security. We suggest a TRNG that exploits the intrinsic static…”
Get full text

Mometasone/Indacaterol/Glycopyrronium and FLU/SAL+ Tiotropium in Patients with Asthma by van Zyl-Smit, Richard N, Chapman, Kenneth R, Kerstjens, Huib A.M, Gessner, Christian, Sagara, Hironori, Tanase, Ana-Maria, Hosoe, Motoi, Pethe, Abhijit, Lawrence, David, Tillmann, Hanns-Christian, D'Andrea, Peter

“…Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA)…”
Get full text

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma by D'Andrea, Peter, Kerstjens, Huib A.M, Hosoe, Motoi, Tanase, Ana-Maria, Gessner, Christian, Chapman, Kenneth R, Tillmann, Hanns-Christian, Sagara, Hironori, Pethe, Abhijit, Lawrence, David, van Zyl-Smit, Richard N

“…Background: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA)…”
Get full text

Performance of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD: Evidence from Clinical and Online Patient Interaction Studies by Patalano, Francesco, Hache, Carolina, Pethe, Abhijit, Kaur, Harneet, Leidy, Nancy Kline, Arsiwala, Tasneem, Afroz, Nuzhat, Gutzwiller, Florian S

“…Patient perception of the burden of chronic bronchitis symptoms in chronic obstructive pulmonary disease (COPD) can be assessed using patient-reported outcome…”
Get full text

Fevipiprant, an oral prostaglandin DP 2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids by Bateman, Eric D, Guerreros, Alfredo G, Brockhaus, Florian, Holzhauer, Björn, Pethe, Abhijit, Kay, Richard A, Townley, Robert G

“…Dose-related efficacy and safety of fevipiprant (QAW039), an oral DP (CRTh2) receptor antagonist, was assessed in patients with allergic asthma uncontrolled by…”
Get full text

Implementation of RRAM based Swish Activation Function and its Derivative on 28nm FD-SOI by Fatima, Afroz, Pethe, Abhijit

“…We propose a novel analog implementation of RRAM based swish activation function and its derivative circuit for inference and training of neuromorphic…”
Get full text

High Mobility Materials and Novel Device Structures for High Performance Nanoscale MOSFETs by Saraswat, K.C., Chi On Chui, Donghyun Kim, Krishnamohan, T., Pethe, A.

“…Channel materials with high mobility are needed for future nodes to meet the ITRS requirements of MOSFETs. In this work we assess the performance of Si, Ge,…”
Get full text

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma by van Zyl-Smit, Richard N, Chapman, Kenneth R, Kerstjens, Huib A M, Gessner, Christian, Sagara, Hironori, Tanase, Ana-Maria, Hosoe, Motoi, Pethe, Abhijit, Lawrence, David, Tillmann, Hanns-Christian, D'Andrea, Peter

“…Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler…”
Get full text